The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
The role of ATP-stimulated P2X1 receptors in human platelets is still unclear. They may act alone or in synergy with other pathways, such as P2Y1 or P2Y12 receptors, to accelerate and enhance calcium mobilisation, shape change and aggregation. To date very few pharmacological means of selectively inhibiting platelet P2X1 receptors have been described, although recent work has shown that suramin is a useful lead compound for the development of high-affinity P2X1 antagonists. We therefore investigated the effects of a series of bivalent and tetravalent suramin analogues on alphabeta meATP (P2X1 receptors)-induced or ADP (P2Y1 receptors)-induced intracellular calcium increases and shape change, as well as on ADP-induced aggregation (P2Y1 & P2Y12 receptors) in human platelets. Changes in intracellular calcium were measured using standard fluorescence techniques, while shape change and aggregation were determined by turbidimetry. The novel tetravalent compound NF864 (8,8',8'',8'''-(carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino)))tetrakis-naphthalene-1,3,5-trisulfonic acid-dodecasodium salt) proved to be the most potent platelet P2X1 antagonist reported to date, blocking alphabeta meATP-induced Ca2+ increases and shape change in a concentration-dependent manner, with a pA2 of 8.17 and 8.49, respectively. The ability to inhibit the platelet P2X1 receptor displayed the following order : NF864 > NF449 > or = NF110 > NF023 = MK-HU1 = suramin. A different antagonistic profile was observed for ADP-induced Ca2+ increases, shape change and aggregation; however, overall four compounds showed sufficient ability to selectively inhibit P2X1 responses, with the order NF110 > NF449 > or = NF864 > or = MK-HU1. Therefore, these compounds should prove useful tools for investigating the functional significance of platelet P2X1 receptors in thrombosis and haemostasis, NF864 being the most promising compound.
Horner
Susanne
S
Department of Pharmacology, University of Frankfurt, Marie-Curie-Strasse 9, 60439, Frankfurt (Main), Germany.
Menke
Kirsten
K
Hildebrandt
Caren
C
Kassack
Matthias U
MU
Nickel
Peter
P
Ullmann
Heiko
H
Mahaut-Smith
Martyn P
MP
Lambrecht
Günter
G
D000244:Adenosine Diphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D001081:Apyrase / Q000037:antagonists & inhibitors; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D048430:Cell Shape / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016018:Least-Squares Analysis; D016014:Linear Models; D010663:Phenylmercury Compounds / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058469:Receptors, Purinergic P2X; D058472:Receptors, Purinergic P2Y1; D013498:Suramin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013873:Thionucleotides / Q000494:pharmacology
C507973:8,8',8'',8'''-(carbonylbis(imino-5,13-benzenetriyl-bis(carbonylimino)))tetrakisnaphthalene-1,3,5-trisulfonic acid; C111914:N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate; C546382:P2RY1 protein, human; D010663:Phenylmercury Compounds; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D058472:Receptors, Purinergic P2Y1; D013873:Thionucleotides; C002910:4-hydroxymercuribenzenesulfonate; D013498:Suramin; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D001081:Apyrase; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D002118:Calcium